Comparison · NCT03472469-d92cbe6f
Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: Number of Participants Discharged From the Hospital With an Opioid Prescription
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: Number of Participants Discharged From the Hospital With an Opioid Prescription. Trial comparisons, record NCT03472469-d92cbe6f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03472469-d92cbe6f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.67 | 0.636 | 0.702 | wilson | |
| Risk in group 2 | 0.615 | 0.58 | 0.649 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0546 | 0.00709 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 1.01 | 1.17 | log | |
| Odds ratio, group 1 over group 2 | 1.27 | 1.03 | 1.56 | log | |
| Number needed to treat, for one more participant with the outcome on Original MMPR - Descending Dose Arm than on MAST MMPR - Escalating Dose Arm | 18.3 | 9.82 | 141 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Original MMPR - Descending Dose Arm | Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter. | 527 | 787 | OG000 |
| Group 2 | MAST MMPR - Escalating Dose Arm | Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter. | 476 | 774 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Discharged From the Hospital With an Opioid Prescription
- Description
- Time frame
- Up to 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- MAST Trial: Multi-modal Analgesic Strategies in Trauma
- NCT number
- NCT03472469
- Phases
- PHASE4
- Conditions
- Nonspecific Pain Post Traumatic Injury
- Interventions
- Acetaminophen IV/PO, Acetaminophen PO, Ketorolac, Celebrex, Naproxen, Tramadol, Pregabalin, Gabapentin, Lidocaine, Opioids, Regional anesthesia
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Results first posted
- 2021-06-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03472469?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03472469-d92cbe6f